对人类mGlu5中的全调节剂的药理学表征
Muhammad Abdur Razzak1, Kevin Tran1, Roisin McCague1
1Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia.
Biochemical pharmacology
|June 7, 2025
概括
甲基氨酸受体5 (mGlu5) 的全调节剂在人类与老鼠模型中显示了特定物种的差异. 这项研究量化了这些变异,对于开发有效的中枢神经系统疾病治疗方法至关重要.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 中枢神经系统功能如认知和记忆中,甲基胺基因组受体5 (mGlu5) 是至关重要的.
- mGlu5功能障碍与神经退行性和神经精神疾病有关,使其成为治疗点.
- 阿洛斯特基调制剂通过微调mGlu5活动提供了一个有前途的治疗策略.
研究的目的:
- 系统地评估和量化各种mGlu5全调节剂对人类mGlu5活动的影响.
- 为了比较人类和老鼠系统之间的mGlu5调节剂的药理特征.
- 鉴定由于物种特异的mGlu5调节器活性差异导致的临床转换的潜在障碍.
主要方法:
- 使用放射性体结合测试来评估体亲和力.
- 采用细胞内 (iCa2+) 调动试验来测量功能反应.
- 使用伊诺西单酸盐 (IP1) 积累测试来评估信号通路.
- 将人类mGlu5数据与公布和新生成的老鼠mGlu5数据进行比较.
主要成果:
- 在人类和老鼠mGlu5之间,在全调节器亲缘关系,合作性和探针依赖性方面,证明了依赖连体的物种差异.
- 观察到,虽然整体调节器药理学相对一致,但存在特定的定量差异.
- 报告了对人类mGlu5的奥思特里克激动剂动力学有积极的全调节器 (PAM) 依赖性影响.
结论:
- 在人体受体上对mGlu5全结合体活性进行系统的评估对于药物设计至关重要.
- 在mGlu5药理学中的特定物种差异可能会对将临床前发现转化为临床环境带来挑战.
- 了解这些差异可以帮助克服转化障碍,并改善针对mGlu的新型中枢神经系统治疗方法的开发.
相关概念视频
Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.2K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.2K
Allosteric Regulation
57.8K
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
57.8K
Cholinergic Receptors: Muscarinic
2.0K
The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine.
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
2.0K
Cooperative Allosteric Transitions
7.9K
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
7.9K
Opioid Receptors: Overview
617
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
617
Allosteric Proteins-ATCase
5.7K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.7K


